Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
NIH Trials Test Anticoagulants for Treating COVID-19
The NIH has launched two of three phase III clinical trials to test the safety and efficacy of different anticoagulants, including heparin and apixaban,...
New York Genome Center Awards Grants to Close Racial Gaps in Cancer Research
As part of its Polyethnic-1000 initiative to increase understanding of racial disparities in the prevalence of certain cancers, The New York Genome Center has...
Trump Signs New Executive Order to Lower Drug Prices Under Medicare
President Donald Trump signed a new executive order on September 13 requiring Medicare to base the prices it pays for drugs on those paid...
FDA Grants Priority Review to Melflufen for Myeloma
The FDA has granted priority review to a New Drug application for INN melphalan flufenamide, or melfufen, in combination with dexamethasone for the treatment...
New Studies Explore Anticoagulation and COVID-19
New studies from the Mount Sinai Health System and NYU Langone Medical Center explore efficacy and risks of anticoagulation in hospitalized patients with COVID-19....
Current Issue
September 2020 Volume 6, Issue 11
This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.